EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression In Preclinical Models

EntreMed, Inc.
(Nasdaq: ENMD), a clinical-stage pharmaceutical company developing
therapeutics for the treatment of cancer and inflammatory diseases,
announced the presentation of preclinical results for its Aurora kinase -
angiogenesis inhibitor, ENMD-981693. The data were presented during oral
and poster presentations by EntreMed scientists at the 2nd Protein Kinases
in Drug Discovery Conference being held May 31 - June 1, 2007 in Boston,
Massachusetts.


ENMD-981693 is an oral, dual-acting kinase inhibitor with a unique
kinase selectivity profile and multiple mechanisms of action. In
preclinical studies, ENMD-981693 has been shown to inhibit a unique profile
of angiogenic tyrosine kinase targets in addition to the Aurora kinases.
Aurora kinases are key regulators of mitosis (cell division), and are often
over-expressed in human cancers. ENMD-981693 is selective for the Aurora A
isoform in comparison to Aurora B.



Results from in vitro studies demonstrate ENMD-981693's potent activity
against oncogenic receptor tyrosine kinases, including FLT3, c-Kit and
CSF1R, which are involved in the pathology of hematological cancers.
Additionally, ENMD-981693 demonstrated potent inhibition of a spectrum of
targets linked to angiogenesis, including KDR (VEGFR2) and FGFR1. The
compound was also shown to induce apoptosis and cell cycle arrest in a
broad range of cell lines.



ENMD-981693 exhibited antiangiogenic activity in in vivo animal models
by preventing the formation of new blood vessels and inducing regression of
formed vessels at well-tolerated doses. Orally-administered ENMD-981693
induced tumor regression with minimal toxicity in a preclinical xenograft
induced by ENMD-981693 in preclinical models of human tumors derived from
colon, leukemia, and breast cancer cell lines.



Mark R. Bray, Ph.D., Vice President, Research at EntreMed, commented on
the presentations, "Results from these preclinical studies highlight the
tremendous progress we have made with this compound and further support our
selection of ENMD-981693 as the lead for our Aurora kinase program.
ENMD-981693 has been shown to induce tumor regression in multiple
preclinical models, which demonstrates the compound's potential clinical
utility in a broad variety of cancers. IND-directed studies are currently
underway and we anticipate the filing of an IND for ENMD-981693 in the
fourth quarter of 2007."



To view the presentations, visit the Recent Presentations section of
the Company's web site at entremed.



About EntreMed



EntreMed, Inc. is a clinical-stage pharmaceutical company developing
therapeutic candidates primarily for the treatment of cancer and
inflammation. Panzem(R) (2-methoxyestradiol or 2ME2), the Company's lead
drug candidate, is currently in multiple Phase 2 clinical trials for
cancer, as well as in preclinical development for rheumatoid arthritis.
MKC-1, an oral cell-cycle regulator, is in various Phase 2 studies for
cancer. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in
advanced cancers. EntreMed's goal is to develop and commercialize new
compounds based on the Company's expertise in angiogenesis, cell-cycle
regulation and inflammation - processes vital to the treatment of cancer
and other diseases, such as rheumatoid arthritis. Additional information
about EntreMed is available on the Company's web site at
entremed and in various filings with the Securities and
Exchange Commission.
















Forward Looking Statements



This release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act with respect to the outlook
for expectations for future financial or business performance (including
the timing of royalty revenues and future R&D expenditures), strategies,
expectations and goals. Forward-looking statements are subject to numerous
assumptions, risks and uncertainties, which change over time.
Forward-looking statements speak only as of the date they are made, and no
duty to update forward-looking statements is assumed. Actual results could
differ materially from those currently anticipated due to a number of
factors, including those set forth in Securities and Exchange Commission
filings under "Risk Factors," including risks relating to the need for
additional capital and the uncertainty of additional funding; variations in
actual sales of Thalomid(R), risks associated with the Company's product
candidates; the early-stage products under development; results in
preclinical models are not necessarily indicative of clinical results,
uncertainties relating to preclinical and clinical trials; success in the
clinical development of any products; dependence on third parties; future
capital needs; and risks relating to the commercialization, if any, of the
Company's proposed products (such as marketing, safety, regulatory, patent,
product liability, supply, competition and other risks).


EntreMed, Inc.

entremed